278 filings
Page 2 of 14
8-K
vzzj5
8 Jun 23
Departure of Directors or Certain Officers
4:12pm
8-K
3tyaw xkd77buf
7 Jun 23
Other Events
8:52am
8-K
ul06cz4y
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
ARS
xscml m0j
21 Apr 23
Annual report to shareholders
4:08pm
DEFA14A
oyibosb
21 Apr 23
Additional proxy soliciting materials
4:05pm
8-K
xxicj
19 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
l8h lke2v
28 Feb 23
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
4:03pm
8-K
jxlx5 pvhubc
5 Jan 23
Termination of a Material Definitive Agreement
5:04pm
8-K
q0q2dc
7 Nov 22
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
1:21pm
8-K
93scja4j
3 Nov 22
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
8s629h1qr50w4lv1ma
3 Aug 22
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
hrehi vybnu5mrtyeev3
30 Jun 22
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
4:06pm
8-K
x26ker916n2 ks6g
13 Jun 22
Departure of Directors or Certain Officers
4:10pm
S-8
mvzq3fxcqr6pd
9 Jun 22
Registration of securities for employees
4:40pm